Beneath the Surface: Guttman-Yassky discusses possible JAK-inhibition, Down syndrome link

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

In this edition, Gelfand, who is also the James J. Leyden Professor of Clinical Investigation and professor of dermatology and epidemiology at University of Pennsylvania’s Perelman School of Medicine, discusses the association between JAK inhibition and Down syndrome comorbidities with Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology and director of the Center of Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai.

Guttman-Yassky and Dusan Bogunovic, PhD, professor of pediatric immunology at Columbia University Vagelos College of Physicians and Surgeons, are leading NIH-funded research into alopecia and eczema in patients with Down syndrome and the efficacy and safety of Janus kinase inhibitors in this population.

Reference:

• Mount Sinai secures over $4 million grant from National Institutes of Health to study alopecia areata and atopic dermatitis in people with Down syndrome. https://www.mountsinai.org/about/newsroom/2024/mount-sinai-secures-over-4-million-grant-from-national-institutes-of-health-to-study-alopecia-areata-and-atopic-dermatitis-in-people-with-down-syndrome. Published July 11, 2024. Accessed Nov. 6, 2024.